Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)

The NIMH-funded Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study was a nationwide public health-focused clinical trial that compared the effectiveness of older (first available in the 1950s) and newer (available since the 1990s) antipsychotic medications used to treat schizophrenia. This page provides information about the study.

Questions and Answers

• Questions and Answers about the NIMH Clinical Antipsychotic Trials of Intervention Effectiveness Study (CATIE) — Phase 2 Results, Published April 1, 2006
• Questions and Answers about the NIMH Clinical Antipsychotic Trials of Intervention Effectiveness Study (CATIE) — Phase 1 Results (September 2005)

News about the CATIE Study

• Press Release (July 2, 2008): Violence in Schizophrenia Patients More Likely Among Those with Childhood Conduct Problems
• Press Release (March 1, 2007): New Details in Schizophrenia Treatment Trial Emerge
• Press Release (Dec. 1, 2006): Older Medication May Be More Cost-Effective for Some Patients with Schizophrenia
• Press Release (Sept. 19, 2005): NIMH Study To Guide Treatment Choices for Schizophrenia (Phase 1 Results)

Related Information

• NIMH Schizophrenia Page
• Director's Update (Dec .1, 2006): NIMH Perspective on Antipsychotic Reimbursement: Using Results from CATIE
• Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) from ClinicalTrials.gov 
• Limited Access Dataset from the CATIE Schizophrenia Study
• Information on CATIE-Alzheimer's Disease (CATIE-AD), a related study:
  • Science Update (April 15, 2009): Use of Antipsychotics in Alzheimer's Patients May Lead to Detrimental Metabolic Changes
  • Press Release (Oct. 11, 2006): Antipsychotic Medications Used to Treat Alzheimer's Patients Found Lacking
• Other studies being conducted by clinical investigators from the CATIE study team include:
  • Comparison of Antipsychotics for Metabolic Problems in the Treatment of People With Schizophrenia or Schizoaffective Disorder (CAMP) 
  • The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study) 
  • Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia